Gene expression deficits in pontine locus coeruleus astrocytes in men with major depressive disorder

Journal of Psychiatry and Neuroscience

Volumn 38, Issue 4, 2013, Pages 276-284

  Chandley, Michelle J ^a   Szebeni, Katalin ^a   Szebeni, Attila ^a   Crawford, Jessica ^a   Stockmeier, Craig A ^b   Turecki, Gustavo ^c   Miguel Hidalgo, Jose Javier ^b   Ordway, Gregory A ^a  

^a East Tennessee State University   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EXCITATORY AMINO ACID TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMIC ACID; NORADRENALIN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; GENE; GENE EXPRESSION; GFAP GENE; GLIA; GLUL GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LASER CAPTURE MICRODISSECTION; LOCUS CERULEUS; MAJOR DEPRESSION; MALE; PONTINE NUCLEUS; REAL TIME POLYMERASE CHAIN REACTION; SLC1A2 GENE; SLC1A3 GENE; WESTERN BLOTTING;

EID: 84879667245     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.120110     Document Type: Article

References (54)

1. Kessler RC, Berglund P, Demler O, et al.; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA 2003;289:3095-105.
2. Warden D, Rush AJ, Trivedi MH, et al. The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep 2007;9:449-59.
3. Ordway GA. Neuropathology of central norepinephrine in psychiatric disorders: postmortem research. In: Ordway GA, Schwartz MA, Frazer A, editors. Brain norepinephrine. 1st ed. Cambridge (UK): Cambridge University Press; 2007:341-62.
4. Ordway GA, Farley JT, Dilley GE, et al. Quantitative distribution of monoamine oxidase A in brainstem monoamine nuclei is normal in major depression. Brain Res 1999;847:71-9.
5. Klimek V, Stockmeier C, Overholser J, et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci 1997;17:8451-8.
6. Klimek V, Roberson G, Stockmeier CA, et al. Serotonin transporter and MAO-B levels in monoamine nuclei of the human brainstem are normal in major depression. J Psychiatr Res 2003;37:387-97.
7. Wong ML, Kling MA, Munson PJ, et al. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotrophin-releasing hormone. Proc Natl Acad Sci U S A 2000;97:325-30.
8. Morilak DA, Barrera G, Echevarria DJ, et al. Role of brain norepinephrine in the behavioral response to stress. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1214-24.
9. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007;62: 1310-6.
10. Kim JS, Schmid-Burgk W, Claus D, et al. Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr 1982;232:299-304.
11. Mitani H, Shirayama Y, Yamada T, et al. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1155-8.
12. Sanacora G, Gueorguieva R, Epperson CN, et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004;61:705-13.
13. Singewald N, Zhou GY, Schneider C. Release of excitatory and inhibitory amino acids from the locus coeruleus of conscious rats by cardiovascular stimuli and various forms of acute stress. Brain Res 1995;704:42-50.
14. Karolewicz B, Szebeni K, Stockmeier CA, et al. Low nNOS protein in the locus coeruleus in major depression. J Neurochem 2004;91: 1057-66.
15. Karolewicz B, Stockmeier CA, Ordway GA. Elevated levels of the NR2C subunit of the NMDA receptor in the locus coeruleus in depression. Neuropsychopharmacology 2005;30:1557-67.
16. Altshuler LL, Abulseoud OA, Foland-Ross L, et al. Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder. Bipolar Disord 2010;12:541-9.
17. Bowley MP, Drevets WC, Ongur D, et al. Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 2002;52:404-12.
18. Ongür D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A 1998; 95:13290-5.
19. Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999;45:1085-98.
20. Bernard R, Kerman IA, Thompson RC, et al. Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol Psychiatry 2011; 16:634-46.
21. Dumais A, Lesage AD, Alda M, et al. Risk factors for suicide completion in major depression: a case-control study of impulsive and aggressive behaviors in men. Am J Psychiatry 2005;162:2116-24.
22. Stockmeier CA, Mahajan GJ, Konick LC, et al. Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 2004;56:640-50.
23. Conner KR, Conwell Y, Duberstein PR. The validity of proxy-based data in suicide research: a study of patients 50 years of age and older who attempted suicide. II. Life events, social support and suicidal behavior. Acta Psychiatr Scand 2001;104:452-7.
24. Kelly TM, Mann JJ. Validity of DSM-III-R diagnosis by psychological autopsy: a comparison with clinician ante-mortem diagnosis. Acta Psychiatr Scand 1996;94:337-43.
25. Austin MC, Whitehead RE, Edgar CL, et al. Localized decrease in serotonin transporter-immunoreactive axons in the prefrontal cortex of depressed subjects committing suicide. Neuroscience 2002;114:807-15.
26. Ordway GA, Szebeni A, Chandley MJ, et al. Low gene expression of bone morphogenetic protein 7 in brainstem astrocytes in major depression. Int J Neuropsychopharmacol 2012;15:855-68.
27. Ordway GA, Szebeni A, Duffourc MM, et al. Gene expression analyses of neurons, astrocytes, and oligodendrocytes isolated by laser capture microdissection from human brain: detrimental effects of laboratory humidity. J Neurosci Res 2009;87:2430-8.
28. Xiang L, Szebeni K, Szebeni A, et al. Dopamine receptor gene expression in human amygdaloid nuclei: elevated D4 receptor mRNA in major depression. Brain Res 2008;1207:214-24.
29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25:402-8.
30. Pitt D, Nagelmeier IE, Wilson HC, et al. Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. Neurology 2003;61:1113-20.
31. Fleige S, Walf V, Huch S, et al. Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR. Biotechnol Lett 2006;28:1601-13.
32. Jacob CP, Koutsilieri E, Bartl J, et al. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis 2007;11:97-116.
33. Jen JC, Wan J, Palos TP, et al. Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures. Neurology 2005;65:529-34.
34. Rao JS, Kellom M, Reese EA, et al. Dysregulated glutamate and dopamine transporters in postmortem frontal cortex from bipolar and schizophrenic patients. J Affect Disord 2012;136:63-71.
35. Miguel-Hidalgo JJ, Waltzer R, Whittom AA, et al. Glial and glutamatergic markers in depression, alcoholism, and their comorbidity. J Affect Disord 2010;127:230-40.
36. Bechtholt-Gompf AJ, Walther HV, Adams MA, et al. Blockade of astrocytic glutamate uptake in rats induces signs of anhedonia and impaired spatial memory. Neuropsychopharmacology 2010;35:2049-59.
37. Karlsson RM, Tanaka K, Saksida LM, et al. Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia. Neuropsychopharmacology 2009;34:1578-89.
38. Lee SG, Su ZZ, Emdad L, et al. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J Biol Chem 2008;283: 13116-23.
39. Mineur YS, Picciotto MR, Sanacora G. Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol Psychiatry 2007;61:250-2.
40. Fumagalli E, Funicello M, Rauen T, et al. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur J Pharmacol 2008;578:171-6.
41. Banasr M, Chowdhury GM, Terwilliger R, et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 2010;15:501-11.
42. Gittins RA, Harrison PJ. A morphometric study of glia and neurons in the anterior cingulate cortex in mood disorder. J Affect Disord 2011;133:328-32.
43. Davis S, Thomas A, Perry R, et al. Glial fibrillary acidic protein in late life major depressive disorder: an immunocytochemical study. J Neurol Neurosurg Psychiatry 2002;73:556-60.
44. Si X, Miguel-Hidalgo JJ, O'Dwyer G, et al. Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacology 2004;29:2088-96.
45. Fatemi SH, Laurence JA, Araghi-Niknam M, et al. Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophr Res 2004;69:317-23.
46. Gosselin RD, Gibney S, O'Malley D, et al. Region specific decrease in glial fibrillary acidic protein immunoreactivity in the brain of a rat model of depression. Neuroscience 2009;159:915-25.
47. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009;65:732-41.
48. Hösli L, Hosli E, Zehntner C, et al. Evidence for the existence of alphaand beta-adrenoceptors on cultured glial cells - an electrophysiological study. Neuroscience 1982;7:2867-72.
49. Fahrig T. Receptor subtype involved and mechanism of norepinephrine-induced stimulation of glutamate uptake into primary cultures of rat brain astrocytes. Glia 1993;7:212-8.
50. Hansson E, Ronnback L. Adrenergic receptor regulation of amino acid neurotransmitter uptake in astrocytes. Brain Res Bull 1992;29:297-301.
51. Aston-Jones G, Ennis M, Pieribone VA, et al. The brain nucleus locus coeruleus: restricted afferent control of a broad efferent network. Science 1986;234:734-7.
52. Valentino RJ, Rudoy C, Saunders A, et al. Corticotropin-releasing factor is preferentially colocalized with excitatory rather than inhibitory amino acids in axon terminals in the peri-locus coeruleus region. Neuroscience 2001;106:375-84.
53. Perea G, Araque A. GLIA modulates synaptic transmission. Brain Res Rev 2010;63:93-102.
54. Banasr M, Duman RS. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry 2008;64:863-70.